Leaflet: information for the user
Olmetec Plus 40 mg/25 mg film-coated tablets
Olmesartan medoxomil / Hydrochlorothiazide
Read this leaflet carefully before you start to take this medicine, because it contains important information for you.
-Keep this leaflet, as you may need to read it again.
-If you have any questions, consult your doctor or pharmacist.
-This medicine has been prescribed for you only, and you must not give it to others even if they have the same symptoms as you, as it may harm them.
-If you experience any side effects, consult your doctor or pharmacist,even if they are not listed in this leaflet. See section 4.
Olmetec Plus contains two active ingredients, olmesartan medoxomilo and hydrochlorothiazide, which are used in the treatment of high blood pressure (hypertension):
Olmetec Plus will only be given if treatment with Olmetec (olmesartan medoxomilo) alone has not adequately controlled your blood pressure. The concurrent administration of both active ingredients in Olmetec Plus contributes to reducing blood pressure more than if each active ingredient were administered alone.
You may already be taking medications to treat high blood pressure, but your doctor may believe it necessary for you to take Olmetec Plus to lower it further.
High blood pressure can be controlled with medications like Olmetec Plus tablets. Your doctor may also have recommended that you make some lifestyle changes to help lower your blood pressure (for example, losing weight, quitting smoking, reducing alcohol consumption, and reducing the amount of salt in your diet). Your doctor may also have recommended that you engage in regular exercise, such as walking or swimming. It is essential to follow your doctor's advice.
If you think you have any of these conditions, or are unsure, do not take the tablets. Talk to your doctor and follow their advice.
Warnings and precautions
Consult your doctor before starting to use Olmetec Plus.
Before taking the tablets,tell your doctorif you are taking any of the following medicines used to treat high blood pressure (hypertension):
Your doctor may check your kidney function, blood pressure, and electrolyte levels in the blood (for example, potassium) at regular intervals.
See also the information under the heading “Do not take Olmetec Plus”.
Before taking the tablets,tell your doctorif you have any of the following health problems:
Contact your doctor if you experience any of the following symptoms:
Your doctor may want to see you more often and perform some tests if you have any of these problems.
Olmetec Plus may cause an increase in lipid and uric acid levels in the blood. Your doctor will probably want to perform blood tests from time to time to monitor these possible changes.
You may experience changes in the levels of certain chemicals in the blood called electrolytes. Your doctor will probably want to perform blood tests from time to time to monitor this possible change. Some signs of electrolyte changes are: thirst, dry mouth, muscle pain or cramps, tired muscles, low blood pressure (hypotension), feeling weak, slow, tired, drowsy, or restless, vomiting, decreased urine output, rapid heart rate.Tell your doctor if you notice any of these symptoms.
As with any other medicine that lowers blood pressure, an excessive decrease in blood pressure in patients with heart or brain blood flow problems can cause a heart attack or stroke. Your doctor will carefully monitor your blood pressure.
If you are to have parathyroid function tests, stop taking Olmetec Plus before the tests are performed.
It is reported to athletes that this medicine contains a component that may establish a positive analytical result for doping control.
Inform your doctor if you are pregnant or think you may be pregnant. Olmetec Plus is not recommended for use at the start of pregnancy, and it should not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if taken during this period (see Pregnancy section).
Children and adolescents
Olmetec Plus is not recommended for children and adolescents under 18 years.
Use of Olmetec Plus with other medicines
Inform your doctor or pharmacist if you are using, have used recently, or may need to use any other medicine.
Particularly, inform your doctor or pharmacist about any of the following medicines:
Your doctor may need to adjust your dose and/or take other precautions:
If you are taking an angiotensin-converting enzyme inhibitor (ACE inhibitor) or aliskiren (see also the information under the headings “Do not take Olmetec Plus” and “Warnings and precautions”).
-Potassium supplements (as well as salt substitutes that contain potassium).
-Diuretics.
-Heparin (to thin the blood).
-Laxatives.
-Glucocorticoids.
-Adrenocorticotropic hormone (ACTH).
-Carbenoxolone (medicine for the treatment of mouth and stomach ulcers).
-Penicillin G sodium (antibiotic also called benzylpenicillin sodium).
-Some analgesics such as aspirin or salicylates.
Taking Olmetec Plus with food and drinks
Olmetec Plus can be taken with or without food.
Be careful when drinking alcohol while taking Olmetec Plus, as some people may feel weak or dizzy. If this happens, do not drink any alcohol, including wine, beer, or drinks with alcohol.
Black patients
As with other similar medicines, the blood pressure-lowering effect of Olmetec Plus is somewhat less in black patients.
Pregnancy and breastfeeding
Pregnancy
Inform your doctor if you are pregnant or think you may be pregnant. Your doctor will advise you to stop taking Olmetec Plus before becoming pregnant or as soon as you know you are pregnant, and will advise you to take another medicine instead of Olmetec Plus. Olmetec Plus is not recommended for use during pregnancy, and it should not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if taken during this period.
Breastfeeding
Inform your doctor if you are breastfeeding or planning to start breastfeeding. Olmetec Plus is not recommended for use in breastfeeding mothers, and your doctor may choose another treatment if you wish to breastfeed.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.
Use in athletes
It is reported to athletes that this medicine contains a component (hydrochlorothiazide) that may establish a positive analytical result for doping control.
Driving and operating machines
You may feel drowsy or dizzy while taking Olmetec Plus for high blood pressure. If this happens, do not drive or operate machines until the symptoms have disappeared. Consult your doctor.
Olmetec Plus contains lactose
This medicine contains lactose. If your doctor has told you that you have a certain sugar intolerance, consult with them before taking this medicine.
Follow exactly the administration instructions for this medication as indicated by your doctor. If in doubt, consult your doctor or pharmacist again.
The recommended doseis 1 Olmetec Plus 40 mg/12.5 mg tablet per day. If blood pressure is not adequately controlled, your doctor may change the dose to 1 Olmetec Plus 40 mg/25 mg tablet per day.
Take the tablets with water. If possible, take your doseat the same time every day, for example, at breakfast time. It is essential to continue taking Olmetec Plus until your doctor tells you to stop.
If you take more Olmetec Plus than you should
If you take more tablets than you should or if a child accidentally ingests one or more tablets, contact your doctor immediately or go to the nearest hospital emergency center and bring the medication packaging with you.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone 91 562 04 20, indicating the medication and the amount ingested.
If you forget to take Olmetec Plus
If you forget to take a dose, take the usual dose the next day.Do nottake a double dose to compensate for the missed doses.
If you interrupt treatment with Olmetec Plus
It is essential to continue taking Olmetec Plus, unless your doctor tells you to stop.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
However, the following side effects may be serious:
Olmetec Plus is a combination of two active principles. The following information, first, describes the side effects reported so far with the combination Olmetec Plus (in addition to those already mentioned) and, second, the known side effects of the two active principles separately.
These are other side effects known so far with Olmetec Plus:
If these effects occur, they are often mild anddo not need to interrupt treatment.
Frequent side effects (may affect up to 1 in 10 people):
Dizziness, weakness, headache, fatigue, chest pain, swelling of ankles, feet, legs, hands, or arms.
Rare side effects (may affect up to 1 in 100 people):
Fast and intense heartbeat (palpitations), hives, eczema, dizziness, cough, indigestion, abdominal pain, nausea, vomiting, diarrhea, muscle cramps, and muscle pain, joint pain, arm and leg pain, back pain, erectile dysfunction in men, blood in urine.
Also, some changes in blood tests have been observed, including:
Increased levels of blood fat, increased urea or uric acid in blood, increased creatinine, increased or decreased levels of potassium in blood, increased levels of calcium in blood, increased blood sugar, increased values of liver function tests. Your doctor will monitor you through a blood test and tell you if you need to take any measures.
Rare side effects (may affect up to 1 in 1,000 people):
Unpleasant sensation, alterations in consciousness, skin swelling (hives), acute renal insufficiency.
Also, some changes in blood test results have been observed, including:
Increased urea nitrogen in blood, decreased values of hemoglobin and hematocrit. Your doctor will monitor you through a blood test and tell you if you need to take any measures.
Additional side effects reported with the use of olmesartan medoxomil or hydrochlorothiazide alone, but not with Olmetec Plus or in a higher frequency:
Olmesartan medoxomil:
Frequent side effects (may affect up to 1 in 10 people):
Bronchitis, cough, congestion and nasal secretion, sore throat, abdominal pain, indigestion, diarrhea, nausea, gastroenteritis, joint or bone pain, back pain, blood in urine, urinary tract infection, flu-like symptoms, pain.
Also, some changes in blood test results have been observed, including:
Increased levels of blood fat, increased urea or uric acid in blood, increased levels of liver or muscle function.
Rare side effects (may affect up to 1 in 100 people):
Fast and intense allergic reactions that can affect the entire body and cause breathing problems, as well as a rapid drop in blood pressure that can even lead to fainting (anaphylactic reactions), inflammation of the face, angina (chest pain or discomfort), unpleasant sensation, skin rash, itching, hives, skin swelling (hives).
Also, some changes in blood test results have been observed, including:
Reduction in the number of a type of blood cell, called platelets (thrombocytopenia).
Rare side effects (may affect up to 1 in 1,000 people):
Renal function deterioration, lack of energy.
Also, some changes in blood test results have been observed, including:
Increased potassium in blood.
Hidroclorotiazida:
Very frequent side effects (may affect more than 1 in 10 people):
Changes in blood tests, including: increased blood fat and uric acid levels.
Frequent side effects (may affect up to 1 in 10 people):
Confusion, abdominal pain, stomach discomfort, feeling of swelling, diarrhea, nausea, vomiting, constipation, glucose excretion in urine.
Also, some changes in blood test results have been observed, including:
Increased creatinine, urea, calcium, and blood sugar levels, decreased levels of chloride, potassium, magnesium, and sodium in blood. Increased serum amylase (hyperamylasemia).
Rare side effects (may affect up to 1 in 100 people):
Loss of appetite, severe difficulty breathing, skin allergic reactions (hypersensitivity reactions), worsening of pre-existing myopia, erythema, skin reactions to light sensitivity, itching, purple spots on the skin due to small hemorrhages (purpura), skin swelling (hives).
Rare side effects (may affect up to 1 in 1,000 people):
Salivary gland inflammation and pain, decreased number of white blood cells, decreased number of platelets in blood, anemia, bone marrow depression, restlessness, depression, sleep problems, feeling of loss of interest (apathy), tingling and numbness, seizures, yellow vision, blurred vision, dry eyes, irregular heartbeat, inflammation of blood vessels, blood clots (thrombosis or embolism), lung inflammation, fluid accumulation in lungs, pancreatitis, jaundice, gallbladder infection, symptoms of lupus erythematosus (such as skin rash, joint pain, and cold hands and fingers), skin allergic reactions, skin peeling and blistering, non-infectious kidney inflammation (interstitial nephritis), fever, muscle weakness(which sometimes causes movement alteration).
Very rare side effects (may affect up to 1 in 10,000 people):
Electrolyte imbalance that can cause abnormally low chloride levels in blood (hypochloremic alkalosis), intestinal obstruction (paralytic ileus).
Acute respiratory distress (symptoms include severe difficulty breathing, fever, weakness, and confusion).
Unknown side effects (the frequencycannot be estimated from the available data):
Decreased vision or eye pain (possible signs offluid accumulation in the vascular layer of the eye (choroidal hemorrhage) oracute angle-closure glaucoma).
Skin cancer and lip cancer (non-melanoma skin cancer).
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for the Vigilance of Medicines for Human Use: https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
No special storage conditions are required.
Do not use this medication after the expiration date that appears on the packaging and on the blister after“CAD”.The expiration date is the last day of the month indicated.
Medications should not be disposed of through drains or in the trash. Dispose of the packaging and unused medications at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of unused packaging and medications. By doing so, you will help protect the environment.
Composition of Olmetec Plus
The active ingredients are:
Olmetec Plus 40 mg/25 mg: each film-coated tablet contains 40 mg of olmesartan medoxomil and 25 mg of hydrochlorothiazide.
The other components are:microcrystalline cellulose, lactose monohydrate*, low-substitution hydroxypropylcellulose, hydroxypropylcellulose, magnesium stearate, titanium dioxide (E171), talc, hypromellose, and iron(III) oxide (E172).
* See previous section “Olmetec Plus contains lactose”“Olmetec Plus contains lactose”
Appearance of the product and contents of the package
Olmetec Plus 40 mg/25 mg film-coated tablets are pink, oval-shaped, 15 x 7 mm tablets with the inscription “C25” on one face.
Olmetec Plus film-coated tablets are available in packages of 14, 28, 30, 56, 84, 90, 98, 10 x 28, and 10 x 30 tablets, and in blister packs of 10, 50, and 500 tablets.
Not all packages are marketed.
Marketing authorization holder
DAIICHI SANKYO ESPAÑA, S.A.
Paseo del Club Deportivo nº1,
Edificio 14, Ground floor left
28223 Pozuelo de Alarcón – Madrid
Spain
Responsible for manufacturing
DAIICHI SANKYO EUROPE GmbH
Luitpoldstrasse 1
85276 Pfaffenhofen
Germany
or
BERLIN-CHEMIE AG
Glienicker Weg 125,
12489 Berlin
Germany
This medicinal product is authorized in the member states of the European Economic Area with the following names:
Austria: Olmetec Plus
Belgium: Olmetec Plus
Denmark: Olmetec Plus
Germany: Olmetec Plus
Greece: Olmetec Plus
Finland: Olmetec Plus
France: CoOlmetec
Iceland: Olmetec Plus
Ireland: Benetor Plus
Italy: Olmegan
Luxembourg: Olmetec Plus
Netherlands: Olmetec HCTZ
Norway: Olmetec Comp
Portugal: Olmetec Plus
Spain: Olmetec Plus
United Kingdom: Olmetec Plus
Last review date of this leaflet:March 2022
Other sources of information
Detailed and updated information on this medicinal product is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.